"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
There have been no reported cases of overdosage with Visicol Tablets. Purposeful or accidental ingestion of more than the recommended dosage of Visicol Tablets might be expected to lead to severe electrolyte disturbances, including hyperphosphatemia, hypocalcemia, hypernatremia, or hypokalemia, as well as dehydration and hypovolemia, with attendant signs and symptoms of these disturbances. Certain severe electrolyte disturbances may lead to cardiac arrhythmias, seizure, renal failure, and death. The patient who has taken an overdosage should be monitored carefully, and treated symptomatically for complications until stable.
Visicol Tablets are contraindicated in the following conditions:
- Biopsy-proven acute phosphate nephropathy
- Gastrointestinal (GI) obstruction
- Gastric bypass or stapling surgery
- Bowel perforation
- Toxic colitis
- Toxic megacolon
- Known allergy or hypersensitivity to sodium phosphate salts or any component of Visicol [see DESCRIPTION]
Last reviewed on RxList: 3/20/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Visicol Information
Visicol - User Reviews
Visicol User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.